References
2. Defronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835.
3. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS-34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 2008;352:854-865.
4. Kahn S, Haffner S, Heis M, et al. Glycemic durability of rosiglitazone, metformin and or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
5. Holman R, Paul S, Bethel MA, et al. 10-Year follow up of intensive control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
6. Nathan D, Buse J, Davidson B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
7. Robarb HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologist medical guideline for clinical practice for the management of diabetes mellitus. Endocrine Practice2007;13:S1-S68.
8. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.
9. Van De Koppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-380.
10. Salera M, Giacomoni P, Pironi L, et al. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 1982;55:329-336.
11. Baggio L, Druker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157.
12. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-3581.
13. Druker DJ. Glucagon-like peptide-1 and the Islet {beta}-cell: augmentation of cell proliferation and inhibition of apoptosis. Mol Endiocrinol 2003;17:161-171.
14. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001;177:35-41.
15. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613.
16. Meneilly GS, McIntosh CH, Pederson RA, et al. Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes. Diabetes Care 2001;24:964-965.
17. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel group study. Lancet 2002;359:824-830.
18. Todd JF, Edwards CM, Ghatei MA, et al. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Clin Sci (Colch) 1998;95:325-329.
19. Victoza (Liraglutide Injection) [package insert]. Princeton, NJ, Novo Nordisk, 2010.
20. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab2008;93:3703-3716.
21. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Med2009;26:268-278.
22. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes (the LEAD-2 Study). Diabetes Care2009;32:84-90.
23. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
24. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met-TZD). Diabetes Care 2009;32:1224-1230.
25. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 Met+SU). Diabetologia 2009;52:2046-2055.
26. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
27. Buse JB, Sesti G, Schmidt W, et al. Switching once daily liraglutide from twice daily exenatide further improves glycemic control in patients with type 2 diabetes using oral medications. Diabetes Care2010;33:1300-1303.
28. Parks M, Rosenbaugh C. Weighing the risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-777.
29. Drucker DJ, Sherman SI, Gorelick FS, et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-433.
30. Parola A. FDA Advisory Committee non-clinical briefing document. New drug application 2009;22-341.
31. Drab SR. Incretin-based therapies for type 2 diabetes mellitus. Pharmacotherapy 2010;30:609-624.
32. Onglyza [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2009.
33. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386.
34. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of sitagliptin monotherapy in treatment naïve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411.
35. DeFronzo R, Hissa M, Garber A, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
36. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.
37. Chacra A, Tan G, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract 2009;63:1395-1406.
38. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinediones alone. J Clin Endocrinol Metab 2009;94:180-189.
39. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes.Diabetes Metab Res Rev 2010;26:540-549
40. Drugstore.com. Accessed May 23, 2010.
41. Sinha A, Rajan M, Hoerger T, et al. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010;33:695-700.